Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 George Medicines & Piramal Pharma Develop Hypertension Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

George Medicines & Piramal Pharma Develop Hypertension Drug

The U.S. Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

George Medicines, a late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO), has developed WIDAPLIK, a new drug for the treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure.

WIDAPLIK is a single pill combination of three medicines—telmisartan, amlodipine, and indapamide—for the treatment of hypertension, developed in three doses (10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg strengths), including two doses that are lower than those currently available in single pill combinations. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications.

George Medicines and Piramal Pharma Solutions began their collaboration on WIDAPLIK in December 2018, when the formulation was developed at Piramal’s Pharmaceutical Development site in Ahmedabad, India. In June 2020, the project was transferred to Piramal’s drug product facility in Pithampur, India, for validation and manufacturing. Leveraging Piramal’s technical expertise and experience advancing innovations, George Medicines achieved FDA approval for WIDAPLIK this year.

“This achievement highlights the value that Piramal Pharma Solutions delivers to its clients and the patients they serve,” said Peter DeYoung, CEO, Piramal Global Pharma. “We are excited to deepen our collaboration with George Medicines, expanding access to transformative treatment options like WIDAPLIK to support our mission and enhance patient outcomes on a global scale.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics